A new survey has found that nearly half of adults in the United States are interested in taking prescription drugs for weight loss, such as Ozempic or Wegovy. In a KFF health tracking poll published on 3 August, researchers reported that 45 per cent of adults said they’d be interested in taking a “safe and effective” prescription drug for weight loss. Meanwhile, seven in 10 adults said they’ve heard at least “a little” about a new class of drugs being used for weight loss, with about one in five saying they have heard “a lot” about these drugs. Ozempic is a type 2 diabetes medication known for its weight loss side effects. Similar semaglutide injections, such as Wegovy and Mounjaro, have been specifically approved for the treatment of obesity and weight loss. This class of drugs called GLP-1 agonists works by mimicking a hormone called glucagon-like peptide 1 (GLP-1), regulating blood sugar levels and slowing down the rate at which food leaves the stomach to create the feeling of fullness. Of the US adults surveyed, older groups were some of the most aware of prescription weight loss drugs, with 76 per cent being those who have been told by a doctor in the past five years that they are overweight or obese. Nearly 60 per cent of those surveyed said they were currently trying to lose weight as well. While there was an overall interest in taking a prescription weight loss drug, that interest significantly decreased when people were asked whether they would take the medication as a routine injection. Only 16 per cent of adults said they would still take Ozempic or Wegovy, even if it wasn’t covered by their health insurance and was not specifically approved by the US Food and Drug Administration for weight loss. In fact, most people believed that insurance companies should cover the cost of weight loss drugs for adults who are overweight or obese, with an overwhelming 80 per cent of adults. Additionally, a large majority of adults believed the substantial profits that pharmaceutical companies have made from increased demand for weight loss drugs is a major factor contributing to the cost of injections like Ozempic and Wegovy. According to Novo Nordisk, the pharmaceutical company behind these prescription drugs for diabetes and weight loss, the list price for Ozempic can cost $935.77 per month without health insurance. Although the majority of adults said they trust pharmaceutical companies like Novo Nordisk to provide “reliable information” about safety and side effects of GLP-1 agonists, only 22 per cent said they trust these companies to price their products fairly. The FDA has listed the most common side effects of taking Wegovy as nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, and digestive disorders. More serious complications can occur from use of Wegovy or Mounjaro, such as the “potential risk of thyroid C-cell tumours,” pancreatitis, gallbladder problems, acute kidney injury, increased heart rate, and suicidal behaviour or thinking. Taking Ozempic can also lead to possible thyroid tumours, including cancer, pancreatitis, changes in vision, and kidney and gallbladder problems. Recently, several patients reported suffering from severe gastroparesis, also known as stomach paralysis, after taking the prescription weight loss medications. In a report from CNN, two people claimed that their “stomachs are paralysed” after taking Ozempic. “I wish I never touched it. I wish I’d never heard of it in my life,” Joanie Knight, a 37-year-old from Louisiana, told CNN. “This medicine made my life hell. So much hell. It has cost me money. It cost me a lot of stress; it cost me days and nights and trips with my family. It’s cost me a lot, and it’s not worth it. The price is too high.” One woman was also diagnosed with cyclic vomiting syndrome, which causes her to throw up multiple times a day. “I’ve almost been off Ozempic for a year, but I’m still not back to my normal,” said Emily Wright, a 38-year-old teacher from Toronto. Shortly after the report, the FDA shared in a statement with The Independent that it has become aware of stomach paralysis occurring among patients taking the medications. “The FDA has received reports of gastroparesis with semaglutide and liraglutide, of which some documented the adverse event as not recovered after discontinuation of the respective product at the time of the report,” the agency said. However, officials clarified that they were unable to determine whether taking Ozempic or Wegovy was the cause of stomach paralysis, or if it was caused by a different issue. “Gastroparesis can be a complication of diabetes that is related to long-standing or poorly controlled disease, further complicating the ability to determine what role the drugs played in the reported events,” the FDA added. In response to reports of stomach paralysis, drug manufacturer Novo Nordisk noted that these medications have been used to treat type 2 diabetes “for more than 15 years”, and for the “treatment of obesity” for eight years. “Semaglutide has been extensively examined in robust clinical development programs, large real world evidence studies and has cumulatively over 9.5 million patient years of exposure,” a spokesperson for Novo Nordisk said in a statement to The Independent. “Gastrointestinal (GI) events are well-known side effects of the GLP-1 class. For semaglutide, the majority of GI side effects are mild to moderate in severity and of short duration. GLP-1’s are known to cause a delay in gastric emptying, as noted in the label of each of our GLP-1 RA medications. Symptoms of delayed gastric emptying, nausea and vomiting are listed as side effects.” Read More Obese people on weight-loss jabs ‘should be prepared to stay on them for life’ Ozempic users report stomach paralysis as weight loss drug side effect: ‘I wish I never touched it’ Sharon Osbourne says she was ‘nauseous’ for weeks after taking Ozempic to lose weight Sharon Osbourne reveals what Ozempic did to her when she was taking it Ozempic users report stomach paralysis as side effect: ‘I wish I never touched it’ Lorraine Candy: ‘Perimenopausal rage made me unravel’

Here's a piece of good, universal advice: Don't share confidential information with an AI chatbot.

AI is coming to the iPhone (eventually). Apple reportedly plans on implementing generative AI technology

TL;DR: As of September 6, get the PiKA3D JR Bundle with 3D pen for just

Tesla has started production of the Cybertruck. The company announced the news on Twitter on

In a heartbreaking memoir, "Sushi Tuesdays," Charlotte Maya bears witness to her late husband's life, death and the aftermath with a singular purpose: to humanize the face of suicide and help readers develop a fluency in discussing mental health.

Tightly packed with new reveals, the Xbox Games Showcase was the closest Summer Game Fest

Nestle is stepping up its project to combat deforestation in Ivory Coast caused by the growth of cocoa farming, bringing cocoa...

The denials came from all angles on media day in Monaco. Speculation that Lewis Hamilton could move to Ferrari next year, in a £40m deal no less, has ramped up this week but was quickly quashed on Thursday by both Hamilton and Ferrari team boss Fred Vasseur. In fact, Hamilton went further, revealing his representatives are “almost there” in agreeing a new deal with Mercedes. The 38-year-old’s current contract with the Silver Arrows – where he has won six of his seven world titles since joining in an inspired decision a decade ago – expires at the end of this season. Despite the wait, the noise from both the Brit and team boss Toto Wolff has been that an extension is a simple inevitability. Not a case of if, but when. “My team is working closely behind the scenes with Toto and we are almost at the end of having a contract ready,” Hamilton stated, affirmatively. These fresh revelations come – coincidentally? – ahead of a huge fortnight for the Brackley-based team. Highly-anticipated upgrades have been long in the making, ever since Wolff finally dismissed the no-sidepod philosophy at the season opener in Bahrain. While the unique streets of Monaco this weekend, due to last week’s cancellation of the race in Imola, represent a somewhat unideal debut for new sidepods, a new floor and a new front suspension, next week in Barcelona will give a genuine representation of any progress made. And, more pertinently, how much the gap is reduced to Red Bull, presently a good distance down the road. Hamilton is, undeniably, reaching the twilight of his career with a record-breaking eighth world championship further away than ever. Links to Ferrari have popped up throughout his 16 years in the sport and Hamilton himself has spoken with confusion, at times, as to why a move has never materialised. The sport’s most prestigious team working in tandem with the sport’s joint-most successful driver? Not now, it seems. But if not now… when? Previous flirtations have been just that. There was no need for Hamilton to broaden his horizons when sat comfortably on his throne. Mercedes were the top dogs for eight years, with Hamilton personally collecting the season gong six times and missing out in the final race twice. Ferrari, meanwhile, have not won a drivers’ title since Hamilton was pipped as a rookie by Kimi Räikkönen way back in 2007. However, now the landscape of the sport is different. Red Bull are the clear frontrunners – perhaps to a level that even surpasses the Mercedes juggernaut. Ferrari and Mercedes are scrapping away to catch up, with Aston Martin this year joining the party. The parallels between now and 11 years ago, when Hamilton shocked the paddock by ditching his boyhood McLaren team to join Mercedes, are comparable. The Brit, as McLaren started their downward spiral, took a Niki Lauda-directed gamble to join the Silver Arrows. “Isn’t that not a bit like moving from Manchester United to West Ham?” asked a jovial Jeremy Clarkson on Hamilton’s second appearance on Top Gear, in 2012. Yet after a season of transition, Hamilton won six world championships in seven years – a streak only split by team-mate Nico Rosberg. His instinct to change paths was justified. To jump at something new. To break with convention. While Ferrari are perhaps on a par with Mercedes currently, they have shown greater potential than their rivals in this new ground-effect era. A 2022 campaign that started with such promise fell away, but the fundamentals of the car seem present. Converting qualifying pace to Sundays seem their current predicament. Hamilton shifting to Maranello next year – which now seems improbable – should not be as unfeasible as it may seem. It would be a plunge in the dark, for sure. A more comfortable decision would be to trust the process at Mercedes, for sure. But these upgrades and their effectiveness in Monaco and Spain, and by extension in Canada, Austria and Silverstone thereafter, will be the clincher. It just depends which way. The likelihood is that improvement will be made, triggering Hamilton signing on the silver dotted line. The man himself has said as much. But until such transformations are made, the driver who made his name by boldly switching sides should not rule out the prancing horse. Has he, perhaps, spoken a little too soon? Not least because, should Ferrari speed away from Mercedes in the coming months, the underlying taste of what if would deny him, and us, of a concluding career narrative as dazzling as it now seems fantasy. Read More Lewis Hamilton provides Mercedes contract latest amid Ferrari links Ferrari boss gives Lewis Hamilton update after reports of shock move Lewis Hamilton and Mercedes are the biggest losers from Imola Grand Prix cancellation F1 Monaco Grand Prix: Why is practice no longer on a Thursday? Bernie Ecclestone would be surprised if Lewis Hamilton wanted to leave Mercedes

Thanks for reading Can We Talk?, a sex and relationships column that aims to tackle the burning questions about sex, dating, relationships, and breakups that you’re too afraid to ask your partner — or maybe even your besties.

TL;DR: The CW's upcoming release schedule is full of hit shows and new content. Unblock

A set of six jerseys that Lionel Messi wore during Argentina's victorious 2022 World Cup run will be auctioned in December, Sotheby's announced Monday, estimating...